DE3587806T2 - Tricyclische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung. - Google Patents

Tricyclische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung.

Info

Publication number
DE3587806T2
DE3587806T2 DE3587806T DE3587806T DE3587806T2 DE 3587806 T2 DE3587806 T2 DE 3587806T2 DE 3587806 T DE3587806 T DE 3587806T DE 3587806 T DE3587806 T DE 3587806T DE 3587806 T2 DE3587806 T2 DE 3587806T2
Authority
DE
Germany
Prior art keywords
processes
preparation
pharmaceutical compositions
compositions containing
tricyclic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3587806T
Other languages
English (en)
Other versions
DE3587806D1 (de
Inventor
Masakuni Okuhara
Hirokazu Tanaka
Toshio Goto
Tohru Kino
Hiroshi Hatanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB848430455A external-priority patent/GB8430455D0/en
Priority claimed from GB858502869A external-priority patent/GB8502869D0/en
Priority claimed from GB858508420A external-priority patent/GB8508420D0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE3587806D1 publication Critical patent/DE3587806D1/de
Publication of DE3587806T2 publication Critical patent/DE3587806T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • C12R2001/55—Streptomyces hygroscopicus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces
    • Y10S435/898—Streptomyces hygroscopicus
DE3587806T 1984-12-03 1985-11-30 Tricyclische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung. Expired - Lifetime DE3587806T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB848430455A GB8430455D0 (en) 1984-12-03 1984-12-03 Fr-900506 substance
GB858502869A GB8502869D0 (en) 1985-02-05 1985-02-05 Ws 7238 substances
GB858508420A GB8508420D0 (en) 1985-04-01 1985-04-01 Fr-900506 & fr-900525 substances

Publications (2)

Publication Number Publication Date
DE3587806D1 DE3587806D1 (de) 1994-06-01
DE3587806T2 true DE3587806T2 (de) 1994-08-25

Family

ID=27262535

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1995175026 Active DE19575026I2 (de) 1984-12-03 1985-11-30 Tricyclische Verbindungen Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung
DE3587806T Expired - Lifetime DE3587806T2 (de) 1984-12-03 1985-11-30 Tricyclische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE1995175026 Active DE19575026I2 (de) 1984-12-03 1985-11-30 Tricyclische Verbindungen Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung

Country Status (24)

Country Link
US (15) US4894366A (de)
EP (1) EP0184162B1 (de)
JP (6) JPH0720970B2 (de)
KR (5) KR930010704B1 (de)
CN (1) CN1013687B (de)
AT (1) ATE104984T1 (de)
AU (1) AU592067B2 (de)
CA (1) CA1338491C (de)
CY (1) CY1912A (de)
DE (2) DE19575026I2 (de)
DK (1) DK169550B1 (de)
ES (1) ES8705038A1 (de)
FI (2) FI87803C (de)
GR (1) GR852904B (de)
HK (1) HK18596A (de)
HU (1) HU195250B (de)
IE (1) IE62865B1 (de)
IL (2) IL92345A (de)
LU (1) LU90317I2 (de)
MX (1) MX9202943A (de)
NL (1) NL960023I2 (de)
NO (1) NO168372C (de)
NZ (1) NZ214407A (de)
PT (1) PT81589B (de)

Families Citing this family (311)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5266692A (en) * 1984-12-03 1993-11-30 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5254562A (en) * 1984-12-03 1993-10-19 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
DE3886265T2 (de) * 1987-06-05 1994-04-28 Fujisawa Pharmaceutical Co Anti-FR-900506-Stoffe-Antikörper und höchstempfindliches Enzym-Immunoassay-Verfahren.
DE3737523A1 (de) * 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
AT400808B (de) * 1987-11-09 1996-03-25 Sandoz Ag Verwendung von tricyclischen verbindungen zur herstellung von topischen arzneimitteln
DE3838035C2 (de) * 1987-11-09 1994-03-24 Sandoz Ag Neue Verwendung von 11,28-dioxa-4-azatricyclo[22.3.1.O·4··,··9·]octacos-18-en-Derivaten
CH677448A5 (de) * 1987-11-09 1991-05-31 Sandoz Ag
US5366971A (en) * 1987-11-09 1994-11-22 Sandoz Ltd. Use of 11,28-dioxa-4-azatricyclo[22.3.1.04,9 ]octacos-18-ene derivatives and pharmaceutical compositions containing them
DE3844904C2 (de) * 1987-11-09 1997-01-30 Sandoz Ag Neue Verwendung von 11,28-Dioxa-4-azatricyclo-[22.3.1.0·4·,·9·]octacos-18-en-Derivaten
JP2799208B2 (ja) 1987-12-09 1998-09-17 フアイソンズ・ピーエルシー マクロ環状化合物
GB8728820D0 (en) * 1987-12-09 1988-01-27 Fisons Plc Compounds
AT407957B (de) * 1987-12-17 2001-07-25 Novartis Erfind Verwalt Gmbh Neue verwendung von 11,28-dioxa-4-azatricyclo- (22.3.1.04,9)octacos-18-en-derivaten und sie enthaltende pharmazeutische zubereitungen
EP0323865A1 (de) * 1988-01-07 1989-07-12 Merck & Co. Inc. Immunopressantes Mittel
DE68921934T2 (de) * 1988-06-29 1995-10-19 Merck & Co Inc Immunsuppressives Agens.
US4981792A (en) * 1988-06-29 1991-01-01 Merck & Co., Inc. Immunosuppressant compound
US5290772A (en) * 1988-06-29 1994-03-01 Merck & Co., Inc. Immunosuppressant agent
ATE131536T1 (de) * 1988-08-01 1995-12-15 Fujisawa Pharmaceutical Co Fr-901154- und fr-901155-derivate, verfahren zu ihrer herstellung
US5202258A (en) * 1988-08-05 1993-04-13 Merck & Co., Inc. Immunosuppressant-producing culture
EP0356399A3 (de) * 1988-08-26 1991-03-20 Sandoz Ag Substituierte 4-Azatricyclo (22.3.1.04.9) octacos-18-en-Derivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen
EP0358508A3 (de) * 1988-09-08 1991-03-20 Merck & Co. Inc. Verbindung zur Unterdrückung der Immunabwehr
CA1316916C (en) * 1988-10-12 1993-04-27 David Askin Hydroxide mediated fk-506 rearrangement product
US4980466A (en) * 1988-10-12 1990-12-25 Merck & Co., Inc. Hydroxide mediated FK-506 rearrangement product
EP0364031B1 (de) * 1988-10-12 1992-12-23 Merck & Co. Inc. Verfahren zur Umlagerung von FK-506 unter Beteiligung von Hydroxid
CH678855A5 (de) * 1988-11-29 1991-11-15 Sandoz Ag
US5268370A (en) * 1989-01-13 1993-12-07 Merck & Co., Inc. Microbial transformation product of L-679,934
EP0378317A3 (de) * 1989-01-13 1990-11-28 Merck & Co. Inc. Mikrobisches Umbildungsprodukt von L-679,934
US4975372A (en) * 1989-01-13 1990-12-04 Merck & Co., Inc. Microbial transformation product of L-683,590
EP0378320A3 (de) * 1989-01-13 1990-11-28 Merck & Co. Inc. Mikrobielles Umwandlungsprodukt
US5272068A (en) * 1989-03-15 1993-12-21 Merck & Co., Inc. Process for producing immunosuppressant agent L-683942 by fermentation
EP0388152B1 (de) * 1989-03-15 1994-10-12 Merck & Co. Inc. Verfahren zur Herstellung einer immunosuppressiven Substanz (demethimmunomycin) durch Verwendung eines Stamm-Mutanten eines Mikroorganismus
DE69015393T2 (de) * 1989-03-15 1995-06-01 Merck & Co Inc Immunosuppressives Mittel.
US5155228A (en) * 1989-03-23 1992-10-13 Merck & Co., Inc. FK-506 C10-C18 process intermediates
US4940797A (en) * 1989-03-23 1990-07-10 Merck & Co., Inc. Process for synthesis of FK-506 C10-C18 intermediates
US5068323A (en) * 1989-04-21 1991-11-26 Merck & Co., Inc. Thermally re-arranged FK-506 derivatives having immunosuppressant activity
US5057608A (en) * 1989-04-21 1991-10-15 Merck & Co., Inc. Immunoregulants, immunosuppressants, process to make ring expanded macrolide related to FK-506/FK-520
EP0399579A1 (de) * 1989-04-21 1990-11-28 Merck & Co. Inc. Makrolide mit immunsuppressiver Wirkung
JPH0368583A (ja) * 1989-05-05 1991-03-25 Merck & Co Inc 新規微生物変換物質
US4987139A (en) * 1989-05-05 1991-01-22 Merck & Co., Inc. FK-520 microbial transformation product
US5270187A (en) * 1989-05-05 1993-12-14 Merck & Co., Inc. Microbial transformation product
IE64214B1 (en) * 1989-06-06 1995-07-26 Fujisawa Pharmaceutical Co Macrolides for the treatment of reversible obstructive airways diseases
US5138052A (en) * 1989-06-13 1992-08-11 Merck & Co., Inc. L-683,590 microbial transformation product
CA2018710A1 (en) * 1989-06-13 1990-12-13 Shieh-Shung T. Chen L-683,590 microbial transformation product
WO1990015805A1 (en) * 1989-06-14 1990-12-27 Sandoz Ltd Heteroatoms-containing tricyclic compounds
US5235066A (en) * 1989-06-30 1993-08-10 Merck & Co., Inc. FK-506 type macrolide intermediate
US5164525A (en) * 1989-06-30 1992-11-17 Merck & Co., Inc. Synthetic process for fk-506 type macrolide intermediates
EP0413532A3 (en) * 1989-08-18 1991-05-15 Fisons Plc Macrocyclic compounds
JPH05504944A (ja) * 1989-08-18 1993-07-29 藤沢薬品工業株式会社 巨大環式化合物
US5011943A (en) * 1989-08-28 1991-04-30 Merck Frosst Canada, Inc. FK-506 C10 -C24 process intermediates
GR1001225B (el) * 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
US5215995A (en) * 1989-10-16 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Hair revitalizing agent
EP0427680B1 (de) * 1989-11-09 1995-08-23 Sandoz Ltd. Heteroatome enthaltende tricyclische Verbindungen
IE904050A1 (en) * 1989-11-13 1991-05-22 Merck & Co Inc Aminomacrolides and derivatives having immunosuppressive¹activity
US5208228A (en) * 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
GB8925797D0 (en) * 1989-11-15 1990-01-04 Fisons Plc Compositions
EP0444829A3 (en) * 1990-02-27 1992-06-03 Fisons Plc Immunosuppressive compounds
US5064835A (en) * 1990-03-01 1991-11-12 Merck & Co., Inc. Hydroxymacrolide derivatives having immunosuppressive activity
US5260301A (en) * 1990-03-01 1993-11-09 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical solution containing FK-506
WO1991013899A1 (en) * 1990-03-12 1991-09-19 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds
IE910847A1 (en) * 1990-03-13 1991-09-25 Fisons Plc Immunosuppressive macrocyclic compounds
US5296489A (en) * 1990-03-13 1994-03-22 Fisons Immunosuppressive macrocyclic compounds
CA2040551A1 (en) * 1990-04-30 1991-10-31 Mark T. Goulet Deoxymacrolide derivatives having immunosuppressive activity
WO1991017754A1 (en) * 1990-05-11 1991-11-28 Fujisawa Pharmaceutical Co., Ltd. Methods for treating and preventing inflammation of mucosa and blood vessels using fk 506 and related compounds
US5643901A (en) * 1990-06-11 1997-07-01 Fujisawa Pharmaceutical Co., Ltd. Medicament for treating idiopathic thrombocytopenic purpura
EP0533930A1 (de) * 1990-06-11 1993-03-31 Fujisawa Pharmaceutical Co., Ltd. Verwendung von einem makrolide sowie fk 506 zur herstellung von arzneimitteln für die behandlung von idiopathic thrombocytopenic purpura und basedow'schen krankheit
US5190950A (en) * 1990-06-25 1993-03-02 Merck & Co., Inc. Antagonists of immunosuppressive macrolides
CA2044846A1 (en) * 1990-06-25 1991-12-26 Thomas R. Beattie Antagonists of immunosuppressive macrolides
US5210030A (en) * 1990-06-25 1993-05-11 Merck & Co., Inc. Process for selectively acylating immunomycin
US5342935A (en) * 1990-06-25 1994-08-30 Merck & Co., Inc. Antagonists of immunosuppressive macrolides
GB9014136D0 (en) * 1990-06-25 1990-08-15 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
MY110418A (en) * 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
GB9014681D0 (en) * 1990-07-02 1990-08-22 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
EP0466365A3 (en) * 1990-07-03 1992-04-15 Merck & Co. Inc. Novel immunosuppressant fermentation products of a microorganism
GB2245891A (en) * 1990-07-09 1992-01-15 Fujisawa Pharmaceutical Co Tricyclo compounds
GB2246350A (en) * 1990-07-23 1992-01-29 Fujisawa Pharmaceutical Co Tricyclo compounds
US5089517A (en) * 1990-08-03 1992-02-18 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection by indolactam v and derivatives thereof
EP0543879A1 (de) * 1990-08-18 1993-06-02 FISONS plc Makrozyklische verbindungen
GB2247620A (en) * 1990-09-07 1992-03-11 Fujisawa Pharmaceutical Co The use of macrolide compounds for cytomegalovirus infection
CA2051872A1 (en) * 1990-09-24 1992-03-25 Kevin M. Byrne Directed biosynthesis process for prolyl-immunomycin
GB2248184A (en) * 1990-09-28 1992-04-01 Fujisawa Pharmaceutical Co New use of macrolide compounds for active oxygen-mediated diseases
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5233036A (en) * 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5348966A (en) * 1990-10-24 1994-09-20 Fujisawa Pharmaceutical Co., Ltd. Method for treating pyoderma and Sezary's syndrome using FK 506 and related compounds
CA2054128A1 (en) * 1990-10-29 1992-04-30 Kevin M. Byrne Process for the production of analogues of immunomycin
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
GB2249787A (en) * 1990-11-19 1992-05-20 Fujisawa Pharmaceutical Co Lactone compounds
GB9027471D0 (en) * 1990-12-19 1991-02-06 Fujisawa Pharmaceutical Co Novel compound
US5194378A (en) * 1991-01-28 1993-03-16 Merck & Co., Inc. Process for producing fk-506
US5116756A (en) * 1991-01-28 1992-05-26 Merck & Co., Inc. Process for producing FK-506
WO1992013862A1 (en) * 1991-02-05 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Lactone compounds
US5147877A (en) * 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
EP0581959B1 (de) * 1991-04-26 2001-01-17 Fujisawa Pharmaceutical Co., Ltd. Verwendung von makrolid-verbindungen gegen augenerkrankungen
US5262533A (en) * 1991-05-13 1993-11-16 Merck & Co., Inc. Amino O-aryl macrolides having immunosuppressive activity
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5250678A (en) * 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
CA2071066A1 (en) * 1991-06-19 1992-12-20 Ali Shafiee Fk-900520 enzymatic and/or microbial methylation products
US5225403A (en) * 1991-06-25 1993-07-06 Merck & Co., Inc. C-21 hydroxylated FK-506 antagonist
US5149701A (en) * 1991-08-01 1992-09-22 Merck & Co., Inc. C-31 methylated FR-900520 cyclic hemiketal immunosuppressant agents
US5273979A (en) * 1991-08-01 1993-12-28 Merck & Co., Inc. C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
US5198358A (en) * 1991-08-28 1993-03-30 Merck & Co., Inc. Microorganism for producing C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
EP0642516B1 (de) * 1991-09-05 2002-06-05 Abbott Laboratories Makrocyclische immunmodulatoren
US5708002A (en) * 1991-09-05 1998-01-13 Abbott Laboratories Macrocyclic immunomodulators
ZA926812B (en) 1991-09-09 1993-04-28 Merck & Co Inc O-heteroaryl,o-alkylheteroaryl,o-alkenylheteroaryl and o-alkynylheteroaryl macrolides having immunosupressive activity
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5252732A (en) * 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5164495A (en) * 1991-09-18 1992-11-17 Abbott Laboratories Method for preparing a dicarboxylic acid half-acid ester of FK506
US5221625A (en) * 1992-01-10 1993-06-22 Merck & Co., Inc. Cyclcic FR-900520 microbial biotransformation agent
EP0624093A1 (de) * 1992-01-28 1994-11-17 KARPAS, Abraham Verwendung einer Verbindung zur Herstellung eines Arzneimittel zur Behandlung einer HIV-Infektion
JP3140228B2 (ja) * 1992-02-17 2001-03-05 ファイザー製薬株式会社 新規な大環状ラクトンおよびその生産菌
US5631235A (en) * 1992-03-02 1997-05-20 Pfizer, Inc. 2-Aminosugar derivatives of macrolides
CA2131372C (en) * 1992-03-02 1998-07-14 Kevin Koch Sugar derivatives of macrolides
JPH07500613A (ja) * 1992-03-02 1995-01-19 ファイザー・インコーポレーテッド 免疫抑制剤及び抗真菌剤としてのマクロライドのデソサミノ誘導体
EP0629208A1 (de) * 1992-03-02 1994-12-21 Pfizer Inc. Fluorzucker makrolid-derivate
DE69302945T2 (de) 1992-03-27 1996-10-10 American Home Prod 29-Demethoxyrapamycin zur Induktion der Immunosuppression
CA2091194A1 (en) * 1992-04-08 1993-10-09 Richard D. Connell 2-oxo-ethyl derivatives as immunosuppressants
HUT66531A (en) * 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
WO1993025533A1 (en) * 1992-06-05 1993-12-23 Abbott Laboratories Methods and reagents for the determination of immunosuppressive agents
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
US5284840A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
US5264355A (en) * 1992-07-02 1993-11-23 Merck & Co., Inc. Methlating enzyme from streptomyces MA6858
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5324644A (en) * 1992-07-28 1994-06-28 Merck & Co., Inc. Process for producing immunosuppressant agent
ATE213272T1 (de) * 1992-08-12 2002-02-15 Fujisawa Pharmaceutical Co Monoklonaler antikörper spezifisch für das fk-506-bindende protein, methode zur bestimmung des gehaltes an fk-506-bindendem protein in einer probe und reagenzsatz dafür
US5365948A (en) * 1992-08-21 1994-11-22 J & W Mcmichael Software Inc. Method for use in treating a patient with FK 506 to prevent an adverse immune response
US5283183A (en) * 1992-09-28 1994-02-01 Merck & Co., Inc. Cyclic FR-900520 microbial biotransformation agent
US5268282A (en) * 1992-09-28 1993-12-07 Merck & Co., Inc. Cyclic FR-900520 microbial biotransformation agent
US5290689A (en) * 1992-09-28 1994-03-01 Merck & Co., Inc. New cyclic FR-900520 microbial biotransformation agent
US5268281A (en) * 1992-09-28 1993-12-07 Merck & Co., Inc. Cyclic FR-900520 microbial biotransformation agent
US5318895A (en) * 1992-10-05 1994-06-07 Merck & Co., Inc. Aspergillus niger mutants
GB9227055D0 (en) * 1992-12-29 1993-02-24 Fujisawa Pharmaceutical Co New use
DE4300478C2 (de) * 1993-01-11 1998-05-20 Eos Electro Optical Syst Verfahren und Vorrichtung zum Herstellen eines dreidimensionalen Objekts
EP0690713A4 (de) * 1993-03-17 1996-04-03 Abbott Lab Substituiertes alicyclisches amin enthaltende makrocyclische immunomodulatoren
AT408520B (de) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Galenische formulierungen
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
GB2279006A (en) * 1993-06-03 1994-12-21 Fujisawa Pharmaceutical Co Treatment of amyotrophic lateral sclerosis
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
US5352783A (en) * 1993-06-09 1994-10-04 Merck & Co., Inc. Microbial transformation product having immunosuppressive activity
US5359060A (en) * 1993-07-06 1994-10-25 Pfizer, Inc. Phosponated derivatives of macrolides
WO1995004061A1 (en) * 1993-07-30 1995-02-09 Abbott Laboratories Activated macrolactams having immunomodulatory activities
GB2281294A (en) * 1993-08-23 1995-03-01 Fujisawa Pharmaceutical Co Process for producing half esters of the macrolide FK506
US5616588A (en) 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
US5898029A (en) * 1994-04-12 1999-04-27 The John Hopkins University Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors
US5880280A (en) * 1994-06-15 1999-03-09 Merck & Co., Inc. Aryl, alkyl, alkenyl and alkynylmacrolides having immunosuppressive activity
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
MX9702699A (es) 1994-10-26 1997-06-28 Novartis Ag Composiciones farmaceuticas.
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
US5616595A (en) * 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
ATE254450T1 (de) 1995-09-19 2003-12-15 Fujisawa Pharmaceutical Co Aerosolzusammensetzungen
ATE340586T1 (de) 1996-07-30 2006-10-15 Novartis Pharma Gmbh Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
KR100244164B1 (ko) * 1997-07-15 2000-03-02 김용옥 수용성 고분자-타크로리무스 접합체 화합물 및 그의 제조 방법
US6562620B2 (en) * 1997-09-19 2003-05-13 Mcgill University Medium to promote islet cell survival
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US20030129215A1 (en) 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US8394398B2 (en) 1997-09-26 2013-03-12 Abbott Laboratories Methods of administering rapamycin analogs with anti-inflammatories using medical devices
US7357942B2 (en) 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US8257725B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US8057816B2 (en) 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
US8257726B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
DE69907418T2 (de) * 1998-02-23 2003-11-13 Fujisawa Pharmaceutical Co Verwendung von makroliden zur behandlung von glaukom
AUPP223198A0 (en) * 1998-03-06 1998-04-02 Fujisawa Pharmaceutical Co., Ltd. New use
TR200002771T2 (tr) 1998-03-26 2001-02-21 Fujisawa Pharmaceutical Co.,Ltd. Devamlı salımı olan preparatlar
DK1098897T3 (da) 1998-07-17 2004-10-18 Agouron Pharma Forbindelser, præparater og fremgangsmåder til stimulation af neuronvækst og -forlængelse
US8257724B2 (en) 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US7960405B2 (en) 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
US7455853B2 (en) 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
KR20010085877A (ko) * 1998-10-02 2001-09-07 추후제출 폴리케타이드 합성 효소와 그 재조합 ｄｎａ 구성물
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
JP2002540211A (ja) * 1999-03-31 2002-11-26 アボット・ラボラトリーズ フォスフェート含有大環免疫調節薬
US6121257A (en) * 1999-03-31 2000-09-19 Abbott Laboratories Sulfamate containing macrocyclic immunomodulators
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US7144880B2 (en) 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
US20060025388A1 (en) * 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
EP2062583B1 (de) 1999-04-30 2012-12-26 The Regents of the University of Michigan Therapeutische Anwendungen proapoptotischer Benzodiazepine
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
GB9917158D0 (en) * 1999-07-21 1999-09-22 Fujisawa Pharmaceutical Co New use
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
US7018405B2 (en) 2000-12-22 2006-03-28 Avantec Vascular Corporation Intravascular delivery of methylprednisolone
US6471980B2 (en) 2000-12-22 2002-10-29 Avantec Vascular Corporation Intravascular delivery of mycophenolic acid
AR033151A1 (es) * 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
US6656460B2 (en) 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
CA2475383C (en) 2002-02-13 2009-12-22 Biogal Gyogyszergyar Rt. Method for extracting a macrolide from biomatter
US7452692B2 (en) * 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
ES2541132T3 (es) * 2002-02-22 2015-07-16 Meda Ab Método para reducir y tratar la inmunosupresión inducida por UV-B
WO2004003214A1 (en) * 2002-06-28 2004-01-08 Biocon Limited Solid state fermentation and fed batch for the production of an immunosuppressant
CN100349627C (zh) 2002-09-06 2007-11-21 艾博特公司 含有水合抑制剂的医疗装置及其制备方法
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
AU2003209664A1 (en) * 2003-02-10 2004-08-30 Biocon Limited Solid state fermentation and fed batch for the production of an immunosuppressant
US20060169199A1 (en) * 2003-03-31 2006-08-03 Vilmos Keri Crystallization and purification of macrolides
WO2004089958A2 (en) 2003-03-31 2004-10-21 TEVA Gyógyszergyár Részvénytársaság Crystallization and purification of macrolides
BRPI0412329A (pt) * 2003-07-09 2006-09-05 Chong Kun Dang Pharm Corp dispersão sólida de tacrolimus e método de processar a mesma
WO2005010015A1 (en) * 2003-07-24 2005-02-03 Teva Gyogyszergyar Reszvenytarsasag Method of purifying macrolides
CA2533339A1 (en) * 2003-08-05 2005-02-10 Kaneka Corporation Stent to be placed in vivo
JP4903568B2 (ja) 2003-08-29 2012-03-28 ベロクシス ファーマシューティカルズ エー／エス タクロリムスを含む固体分散体
AU2004267910B2 (en) 2003-08-29 2011-01-06 Veloxis Pharmaceuticals, Inc. Solid dispersions comprising tacrolimus
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
WO2005038009A2 (en) * 2003-10-17 2005-04-28 Ranbaxy Laboratories Limited Production of tacrolimus (fk-506) using new streptomyces species
SG148198A1 (en) 2003-11-21 2008-12-31 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
RU2317991C1 (ru) * 2003-12-05 2008-02-27 Байокон Лимитид Способ выделения и очистки макролидов
KR100485877B1 (ko) * 2003-12-30 2005-04-28 종근당바이오 주식회사 타크롤리무스를 생산하는 미생물 및 이를 이용한타크롤리무스의 대량 생산방법
US20050176080A1 (en) * 2004-02-10 2005-08-11 Vani Bodepudi Hapten, immunogens and derivatives of ascomycin useful for preparation of antibodies and immunoassays
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
ATE534424T1 (de) 2004-03-19 2011-12-15 Abbott Lab Mehrfache arzneiabgabe aus einem ballon und eine prothese
DK1756290T3 (en) * 2004-04-12 2016-08-22 Biocon Ltd Streptomyces sp. BICC 7522 AND THE USE THEREOF FOR THE PRODUCTION OF MACRO-LIDER
US20090275099A1 (en) * 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
JP2006014722A (ja) 2004-06-02 2006-01-19 Keio Gijuku 遺伝子マーカー及びその利用
EP1768662A2 (de) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immunstimulatoren kleiner moleküle und assays für deren nachweis
CA2571899A1 (en) * 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
MX2007002808A (es) * 2004-09-10 2007-10-10 Ivax Pharmaceuticals Sro Proceso para el aislamiento de tacrolimus cristalino.
CA2580123A1 (en) * 2004-09-10 2006-03-23 Ivax Pharmaceuticals S.R.O. Process for isolation of macrolide compounds
GT200500282A (es) * 2004-10-12 2006-05-04 Heteroatomos conteniendo compuestos triciclicos.
ITMI20042098A1 (it) * 2004-11-03 2005-02-03 Antibioticos Spa Processo per la purificazione di tacrolimus
US7439252B2 (en) * 2004-12-01 2008-10-21 TEVA Gyógyszergyár Zártkörúen Müködö Részvénytársaság Ascomycin crystalline forms and preparation thereof
JP2008524239A (ja) * 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミティド ナノ粒子のタクロリムス製剤
EP1828204A1 (de) * 2004-12-22 2007-09-05 Teva Gyogyszergyár Zártköruen Muködo Részvenytarsaság Verfahren zur aufreinigung von makroliden
EP1845996A4 (de) * 2005-01-03 2009-04-29 Univ Michigan Zusammensetzungen und verfahren in zusammenhang mit neuen verbindungen und targets dafür
EP1833835A1 (de) * 2005-01-05 2007-09-19 Teva Gyogyszergyar Zartkoruen Müködö R Szv Nytarsa Amorpher tacrolimus und herstellung
ATE532064T1 (de) * 2005-01-13 2011-11-15 Univ Keio Genmarker und dessen verwendung
EP1868663B1 (de) 2005-03-23 2011-11-16 Abbott Laboratories Abgabe von stark lipophilen mitteln durch medizinprodukte
JP5242374B2 (ja) 2005-03-23 2013-07-24 アボット・ラボラトリーズ 組成物ならびに長期効力を得るための医療機器を用いたラパマイシン類縁体の投与方法
WO2007053193A2 (en) 2005-06-01 2007-05-10 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
CN1876822B (zh) * 2005-06-06 2010-05-12 上海市农药研究所 他克莫司的产生菌株及生产方法
WO2007013017A1 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited A process for purification of macrolides
ITMI20051549A1 (it) * 2005-08-05 2007-02-06 Antibioticos Spa Purificazione del tacrolimus su supporti dimorigine vegetale
WO2007029082A2 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited An improved fermentation process for preparing ascomycin
US20080318289A1 (en) * 2005-10-05 2008-12-25 Parveen Kumar Fermentation Processes for the Preparation of Tacrolimus
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
CA2628193C (en) 2005-11-01 2012-08-14 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
US7678901B2 (en) 2006-02-28 2010-03-16 Wyeth Rapamycin analogs containing an antioxidant moiety
US7622477B2 (en) 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
DE602007006601D1 (de) * 2006-03-15 2010-07-01 Teva Gyogyszergyar Zartkoeruee Verfahren zur reinigung von tacrolimus
US8022188B2 (en) * 2006-04-24 2011-09-20 Abbott Laboratories Immunosuppressant binding antibodies and methods of obtaining and using same
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
MX2008015488A (es) 2006-06-09 2009-02-12 Univ Michigan Composiciones y metodos relacionados con compuestos novedosos y objetivos de los mismos.
JPWO2008026781A1 (ja) 2006-08-31 2010-01-21 直人 奥 逆標的化脂質小胞体
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
CA2668134A1 (en) * 2006-11-06 2008-05-15 Teva Gyogyszergyar Zartkoerueen Muekoedoe Reszvenytarsasag Ascomycin and pimecrolimus having reduced levels of des-methylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof
WO2008127746A1 (en) 2007-01-10 2008-10-23 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
WO2008109347A2 (en) * 2007-03-02 2008-09-12 Yale University Methods for ex vivo administration of drugs to grafts using polymeric nanoparticles
MX2009009645A (es) 2007-03-09 2009-11-19 Univ Michigan Composiciones y metodos relacionados con nuevos compuestos y objetivos de los mismos.
LT2167033T (lt) 2007-05-30 2017-08-10 Veloxis Pharmaceuticals A/S Kartą per dieną vartojama geriamoji vaisto forma, apimanti takrolimą
KR100891313B1 (ko) 2007-08-17 2009-03-31 (주) 제노텍 담체로 작용하는 흡착성 수지의 제공에 의한 트리사이클로화합물의 생산 및 추출 방법
CA2698248C (en) 2007-09-14 2017-08-29 The Regents Of The University Of Michigan Phenyl acyl guanidine derivatives as f1f0-atpase inhibitors and the use thereof
AU2008323945B2 (en) 2007-11-06 2013-11-28 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
EP2245165A4 (de) * 2008-01-11 2011-06-01 Massachusetts Eye & Ear Infirm Transgene konditionalstopp-dimerisierbare-caspase-tiere
KR101003042B1 (ko) 2008-03-17 2010-12-21 종근당바이오 주식회사 고순도 타크로리무스의 정제 방법
JP2011517410A (ja) * 2008-04-08 2011-06-09 アミリス バイオテクノロジーズ， インコーポレイテッド 異種配列の発現
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
AU2009291632B2 (en) 2008-09-11 2013-04-04 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
KR100910165B1 (ko) * 2008-09-18 2009-07-30 (주) 제노텍 은 이온 용액 추출을 이용한 불포화 알킬기를 가진 락톤 화합물 정제방법
WO2010041684A1 (ja) * 2008-10-08 2010-04-15 高田製薬株式会社 タクロリムス外用剤
SG172361A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside analogs
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
CN101712686B (zh) * 2009-06-22 2012-08-29 鲁南制药集团股份有限公司 一种发酵液中他克莫司的分离纯化方法
EP2272963A1 (de) * 2009-07-09 2011-01-12 LEK Pharmaceuticals d.d. Verfahren zur Herstellung von Tacrolimus
WO2011035124A1 (en) 2009-09-18 2011-03-24 The Regents Of The University Of Michigan Benzodiazepinone compounds and methods of treatment using same
CA2780333C (en) 2009-11-17 2016-05-24 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
WO2011062766A2 (en) 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
US8951595B2 (en) 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
US8480620B2 (en) 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
PT2575769T (pt) 2010-02-17 2016-09-22 Veloxis Pharmaceuticals As Composição de tacrolímus estabilizada
EP2752422B1 (de) 2010-03-31 2017-08-16 Gilead Pharmasset LLC Stereoselektive synthese von phosphorhaltigen wirkstoffen
US20110318277A1 (en) 2010-06-25 2011-12-29 APT Pharmaceuticals, Inc. University of Maryland, Baltimore Tacrolimus compositions for aerosol administration
KR101261131B1 (ko) 2010-08-24 2013-05-06 이화여자대학교 산학협력단 신규 타크롤리무스 유도체, 상기 유도체를 포함하는 신경 보호용 조성물, 상기 유도체를 포함하는 면역 억제용 조성물, 상기 유도체의 생산 방법 및 상기 유도체의 생산 균주
MA34586B1 (fr) 2010-08-25 2013-10-02 Medis Lab Particules cristallines de tacrolimus micronise a surface modifiee et compositions pharmaceutiques associees
US10117411B2 (en) 2010-10-06 2018-11-06 Dow Agrosciences Llc Maize cytoplasmic male sterility (CMS) C-type restorer RF4 gene, molecular markers and their use
PT2683406T (pt) 2011-03-11 2019-07-08 Beth Israel Deaconess Medical Ct Inc Anticorpos anti-cd40 e utilização dos mesmos
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
SI2970101T1 (sl) 2013-03-14 2018-09-28 Alkermes Pharma Ireland Limited Prozdravila fumaratov in njihova uporaba pri zdravljenju različnih bolezni
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
AU2014248090B2 (en) 2013-04-03 2018-08-02 N-Fold Llc Novel nanoparticle compositions
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
CN104650112B (zh) * 2013-11-18 2018-07-31 山东新时代药业有限公司 他克莫司8-丙基类似物的制备方法
UY35927A (es) 2013-12-31 2015-07-31 Dow Agrosciences Llc ?gen restaurador rf3 de tipo s de la esterilidad masculina citoplasmática del maíz (cms), marcadores moleculares y sus usos?.
WO2015106283A1 (en) * 2014-01-13 2015-07-16 Amplyx Pharmaceuticals, Inc. Antifungal compounds
US10428331B2 (en) 2014-01-16 2019-10-01 Musc Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
ES2753361T3 (es) 2014-02-24 2020-04-08 Alkermes Pharma Ireland Ltd Sulfonamida y profármacos de fumaratos de sulfinamida y su uso en el tratamiento de diversas enfermedades
KR101694879B1 (ko) * 2014-08-01 2017-01-12 주식회사 인트론바이오테크놀로지 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도
US10143682B2 (en) 2014-10-28 2018-12-04 Koushi Yamaguchi Medicine for improving state of pregnancy, and use thereof
KR20180041704A (ko) 2015-08-19 2018-04-24 비버스 인크. 제약 제제
CN116063481A (zh) 2015-09-04 2023-05-05 普里玛托普医疗股份有限公司 人源化抗-cd40抗体及其用途
CN106074367A (zh) * 2016-07-20 2016-11-09 中山大学中山眼科中心 含fk506类化合物/fkbp蛋白二聚体的药物组合物及其制备方法
CN108384819B (zh) * 2017-02-03 2021-06-25 上海医药工业研究院 一种用于发酵他克莫司的培养基以及发酵方法
RU2686779C1 (ru) * 2018-07-26 2019-04-30 Общество с ограниченной ответственностью "Изварино Фарма" Штамм streptomyces tsukubensis - продуцент такролимуса и способ получения такролимуса
CN112533599A (zh) 2018-08-10 2021-03-19 山口晃史 与母体和胎儿的关系中的体液免疫相关的疾病的治疗药
WO2020076738A2 (en) * 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
EP3930713A4 (de) 2018-12-04 2022-11-16 Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi Stabile tacrolimus-salbenformulierung zur topischen behandlung von hauterkrankungen
KR102135527B1 (ko) * 2018-12-18 2020-07-20 이문수 발가락 습기 제거 양말
EP3900729A4 (de) 2018-12-18 2022-09-07 Koushi Yamaguchi Mittel zur verbesserung von unfruchtbarkeit, wiederholten fehlgeburten und schwangerschaftszuständen
GR1009790B (el) 2019-03-20 2020-08-03 Φαρματεν Α.Β.Ε.Ε. Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει τακρολιμους
WO2022187379A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3244592A (en) * 1962-06-09 1966-04-05 Arai Tadashi Ascomycin and process for its production
JPS54110000A (en) * 1978-02-17 1979-08-29 Kaken Pharmaceut Co Ltd Novel streptovaricin c derivative
US4309504A (en) * 1980-01-28 1982-01-05 Eli Lilly And Company Process for preparing narasin
US4654334A (en) * 1980-10-08 1987-03-31 International Minerals & Chemical Corp. Manganese-containing antibiotic agents
US4390546A (en) * 1981-12-07 1983-06-28 Merck & Co., Inc. Antiparasitic macrolide from a strain of Streptomyces hygroscopicus
US4415669A (en) * 1981-12-07 1983-11-15 Merck & Co., Inc. Substance and process for its production
US4510317A (en) * 1983-07-28 1985-04-09 Hoffmann-La Roche Inc. Antibiotic X-14934A
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8430455D0 (en) * 1984-12-03 1985-01-09 Fujisawa Pharmaceutical Co Fr-900506 substance
US5254562A (en) * 1984-12-03 1993-10-19 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5266692A (en) * 1984-12-03 1993-11-30 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
CH677448A5 (de) * 1987-11-09 1991-05-31 Sandoz Ag
US5956352A (en) * 1992-04-24 1999-09-21 Digital Equipment Corporation Adjustable filter for error detecting and correcting system

Also Published As

Publication number Publication date
DK556285D0 (da) 1985-11-29
JPH0720970B2 (ja) 1995-03-08
EP0184162A2 (de) 1986-06-11
FI864527A (fi) 1986-11-07
CN1013687B (zh) 1991-08-28
IE62865B1 (en) 1995-03-08
US5565559A (en) 1996-10-15
DE19575026I2 (de) 2002-03-28
KR930010706B1 (ko) 1993-11-08
JP3211891B2 (ja) 2001-09-25
JPH0372483A (ja) 1991-03-27
AU592067B2 (en) 1990-01-04
US6028097A (en) 2000-02-22
JPH0372484A (ja) 1991-03-27
US5624842A (en) 1997-04-29
FI85977C (fi) 1992-06-25
US4894366A (en) 1990-01-16
NO168372C (no) 1992-02-12
FI864527A0 (fi) 1986-11-07
HUT41842A (en) 1987-05-28
CA1338491C (en) 1996-07-30
US4956352A (en) 1990-09-11
JP2746134B2 (ja) 1998-04-28
JPH0346445B2 (de) 1991-07-16
JP2976966B2 (ja) 1999-11-10
ATE104984T1 (de) 1994-05-15
US20030229115A1 (en) 2003-12-11
PT81589A (en) 1986-01-01
US5110811A (en) 1992-05-05
US5830717A (en) 1998-11-03
KR930010705B1 (ko) 1993-11-08
DK169550B1 (da) 1994-11-28
IL92345A (en) 1991-06-10
JP2828091B2 (ja) 1998-11-25
MX9202943A (es) 1992-06-30
US20040029908A1 (en) 2004-02-12
IE852971L (en) 1986-06-03
IL77222A (en) 1991-06-10
GR852904B (de) 1986-04-01
CN85109492A (zh) 1986-06-10
FI854731A (fi) 1986-06-04
KR930010707B1 (ko) 1993-11-08
HU195250B (en) 1988-04-28
JPH07224066A (ja) 1995-08-22
ES8705038A1 (es) 1987-04-16
NL960023I1 (nl) 1996-12-02
US6482845B1 (en) 2002-11-19
EP0184162B1 (de) 1994-04-27
US5496727A (en) 1996-03-05
JPH1067783A (ja) 1998-03-10
NL960023I2 (nl) 1997-06-02
DK556285A (da) 1986-06-04
FI85977B (fi) 1992-03-13
US4929611A (en) 1990-05-29
ES549478A0 (es) 1987-04-16
NO168372B (no) 1991-11-04
US6201005B1 (en) 2001-03-13
FI87803B (fi) 1992-11-13
DE3587806D1 (de) 1994-06-01
EP0184162A3 (en) 1989-02-08
LU90317I2 (fr) 1999-01-11
NZ214407A (en) 1989-11-28
AU5059685A (en) 1986-06-12
US20050124646A1 (en) 2005-06-09
NO854833L (no) 1986-06-04
FI87803C (fi) 1993-02-25
KR860004918A (ko) 1986-07-16
PT81589B (pt) 1987-10-20
HK18596A (en) 1996-02-09
KR930010708B1 (ko) 1993-11-08
JPH1112281A (ja) 1999-01-19
CY1912A (en) 1985-11-30
FI854731A0 (fi) 1985-11-29
KR930010704B1 (ko) 1993-11-08
JPH11343294A (ja) 1999-12-14
US20030170831A1 (en) 2003-09-11

Similar Documents

Publication Publication Date Title
DE3587806T2 (de) Tricyclische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung.
DE59208559D1 (de) Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ATE58534T1 (de) 2-pyrimidinyl-l-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ATE45153T1 (de) Benzisoselenazolthione, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische produkte.
ATE324T1 (de) Hydroxypropyl-triazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
JPS5665869A (en) Novel 22hydroxyalkyll3*4*55trihydroxyypiperidine compound* its manufacture and drug
ATE19773T1 (de) Nitroaliphatische verbindungen, verfahren zu deren herstellung und deren verwendung.
ATE18226T1 (de) Pyrrolo(2,3-d)carbazolderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung.
ATE200492T1 (de) 7-acyl-3-(substituierte carbamoyloxy) cephem verbindungen, verfahren zu ihrer herstellung und anwendung
ATE37369T1 (de) Eine thiazinverbindung, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE291T1 (de) Fluorenyl-azolylmethyl-carbinole, verfahren zu ihrer herstellung, arzneimittel, die diese verbindungen enthalten und verfahren zur herstellung dieser arzneimittel.
ES8308471A1 (es) "un procedimiento para la preparacion de composiciones efectivas contra acaros".
ATE275576T1 (de) Ungesättigte 14,15-cyclopropano-androstane, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
ATE25517T1 (de) Delta-1-pyrrolin-thiolactimaether und verfahren zu ihrer herstellung.
IL110865A (en) Difluoro statone analogs process for their preparation and pharmaceutical compositions containing them
ATE32514T1 (de) 3-(4'-aminobutylamino)-propylamino-bleomycinderivate, verfahren zur ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE38837T1 (de) Gesaettigten stickstoff enthaltende tricyclische dione, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
ATE49003T1 (de) Pregnane derivate, verfahren zu ihrer herstellung und pharmazeutische zusammenstellungen, die sie enthalten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
V448 Application of spc

Free format text: PRODUCT NAME: TACROLIMUS (INN); REGISTRATION NO/DATE: 30793.00.00, 30793.00.01, 30793.01.00; 19950321

Spc suppl protection certif: 195 75 026

Filing date: 19950727

V457 Spc granted

Free format text: PRODUCT NAME: TACROLIMUS (INN); REGISTRATION NO/DATE: 30793.00.00, 30793.00.01, 30793.01.00; 19950321

Spc suppl protection certif: 195 75 026

Filing date: 19950727

V464 Spc expired

Free format text: PRODUCT NAME: TACROLIMUS (INN); REGISTRATION NO/DATE: 30793.00.00, 30793.00.01, 30793.01.00; 19950321

Spc suppl protection certif: 195 75 026

Filing date: 19950727